Research has revealed that the global female infertility pharmaceutical market will increase to be worth $2.5 billion by the end of the forecast period.
List view / Grid view
Filter the results
28 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The results of ObsEva’s trial of OBE001 (nolasiban) showed improvement in clinical pregnancy and live birth rates in women undergoing embryo transfer...
20 September 2016 | By Ernest Loumaye, MD, PhD, Co-Founder & Chief Executive Officer, ObsEva
Ernest Loumaye, PhD, Co-Founder & Chief Executive Officer of ObsEva discusses the unmet need of women's reproductive health and what's in the pipeline for treatment...
28 July 2016 | By ObsEva
ObsEva initiates Phase 1 clinical program of OBE022, a first-in-class orally active Prostaglandin F2alpha antagonist, for the treatment of preterm labor...